Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference
Olema Oncology (Nasdaq: OLMA) will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Wednesday, December 3, 2025 at 12:55 p.m. ET. The company is a clinical-stage biopharmaceutical focused on targeted therapies for breast cancer and related indications.
Live webcasts and recordings will be available, as permitted by the event host, in the Events and Presentations section of Olema’s investor relations website at ir.olema.com.
Olema Oncology (Nasdaq: OLMA) parteciperà a un colloquio informale al 8th Annual Evercore Healthcare Conference il mercoledì 3 dicembre 2025 alle 12:55 ET. L'azienda è una biopharma in fase clinica focalizzata su terapie mirate per il cancro al seno e indicazioni correlate.
Le webcast in diretta e le registrazioni saranno disponibili, per quanto consentito dall'organizzatore dell'evento, nella sezione Eventi e Presentazioni del sito di relazioni con gli investitori di Olema all'indirizzo ir.olema.com.
Olema Oncology (Nasdaq: OLMA) participará en una charla informal durante la 8th Annual Evercore Healthcare Conference el miércoles, 3 de diciembre de 2025 a las 12:55 p.m. ET. La empresa es una biotecnológica clínica enfocada en terapias dirigidas para el cáncer de mama y indicaciones relacionadas.
Las transmisiones en directo y las grabaciones estarán disponibles, según lo permita el anfitrión del evento, en la sección Eventos y Presentaciones del sitio de relaciones con inversionistas de Olema en ir.olema.com.
Olema Oncology (나스닥: OLMA)는 8th Annual Evercore Healthcare Conference의 화롯대 대화(fireside chat)에 참가할 예정이며 2025년 12월 3일 수요일 오후 12:55 ET에 열립니다. 이 회사는 유방암 및 관련 적응증에 대한 표적 치료에 중점을 둔 임상 단계 생물의약 회사입니다.
주최 측의 허용 범위 내에서 Olema의 투자자 관계 웹사이트 ir.olema.com의 Events and Presentations 섹션에서 라이브 웹캐스트 및 녹화를 이용하실 수 있습니다.
Olema Oncology (Nasdaq: OLMA) participera à une conversation informelle lors de la 8th Annual Evercore Healthcare Conference le mercredi 3 décembre 2025 à 12 h 55, heure de l'Est. L'entreprise est une biopharmaceutique en phase clinique axée sur des thérapies ciblées pour le cancer du sein et les indications associées.
Des webcasts en direct et des enregistrements seront disponibles, sous réserve de l'autorisation de l'hôte de l'événement, dans la section Événements et Présentations du site des relations investisseurs d'Olema à l'adresse ir.olema.com.
Olema Oncology (Nasdaq: OLMA) nimmt an einem fireside chat bei der 8th Annual Evercore Healthcare Conference am Mittwoch, dem 3. Dezember 2025 um 12:55 Uhr ET teil. Das Unternehmen ist ein klinisch erprobtes Biopharma-Unternehmen, das sich auf zielgerichtete Therapien für Brustkrebs und verwandte Indikationen konzentriert.
Live-Webcasts und Aufzeichnungen werden, soweit vom Veranstalter gestattet, im Bereich „Events and Presentations“ der Investor-Relations-Website von Olema unter ir.olema.com verfügbar sein.
Olema Oncology (ناسداك: OLMA) ستشارك في جلسة حوارية تقودها المدفأة خلال أطول مؤتمر Evercore للرعاية الصحية السنوي الثامن يوم الأربعاء 3 ديسمبر 2025 الساعة 12:55 مساءً بتوقيت شرق الولايات المتحدة. الشركة شركة أدوية حيوية مخبرية في مرحلة سريرية تركز على العلاجات الموجهة لسرطان الثدي والمؤشرات ذات الصلة.
سيكون البث المباشر والمواد المسجلة مجانية حسب ما يسمح به مضيف الحدث، في قسم الأحداث والعروض من موقع علاقات المستثمرين لشركة Olema على العنوان ir.olema.com.
- None.
- None.
SAN FRANCISCO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Wednesday, December 3, 2025 at 12:55 p.m. ET.
Live webcasts and recordings of these presentations will be available, as permitted by the event host, in the Events and Presentations section of Olema’s investor relations website at ir.olema.com.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
FAQ
When will Olema Oncology (OLMA) present at the Evercore Healthcare Conference?
Where can I watch the Olema (OLMA) fireside chat webcast?
What topics will Olema (OLMA) likely cover at the December 3, 2025 presentation?
How can investors access the Olema (OLMA) presentation slides or replay after the Evercore event?
Will Olema (OLMA) management be available for investor Q&A at the Evercore Healthcare Conference?
